RGC Resources NASDAQ: RGCO reported higher second-quarter earnings for fiscal 2026, citing increased Roanoke Gas margins from new rates that took effect Jan. 1, higher earnings from its unconsolidated affiliate MVP and lower interest expense. The company also discussed operational headwinds, including the shutdown of a large customer's facility and damage at its LNG peak-shaving facility.
Regencell Bioscience Holdings Limited has surged 23,745% in 2025, reaching a $12b market cap despite having zero revenue. RGC's explosive upside is driven by float mechanics, with the founder and his wife locking up most of the free float. Recent SEC filings and a 35-for-1 reverse stock split have increased accessibility and meme stock potential, fueling further price momentum.
Finding top growth stocks with the kind of capital appreciation upside long-term investors are seeking is the name of the game for a solid majority of investors in the market right now.
RGC Resources is transitioning from a stable, dividend-focused utility to a growth story with the launch of the Mountain Valley Pipeline (MVP). RGCO's earnings and cash flows are set to rise as MVP operations contribute real profits, supporting higher dividends and potential stock revaluation. The company's strong regulatory position, monopoly advantage, and history of dividend growth make RGCO attractive for income and growth investors.
RGCO is entering a high cash flow phase from past investments, notably with the Mountain Valley Pipeline now operational, supporting a strong buy rating. Q2 2025 results exceeded expectations, marking a turning point as the company shifts from investment to active cash generation, with improved interest coverage. The regulated business, favorable rate case, and 20-year dividend growth history provide stability, while MVP offers a major new profit stream.
RGC Resources, a small natural gas utility in Virginia, serves 63,400 customers and offers a 3.70% dividend yield, appealing for income-seeking investors. Despite its small size, RGC Resources remains liquid for individual investors, though institutional investors might face challenges due to lower trading volumes. The company's growth prospects include expanding into Franklin County, despite demographic challenges in Roanoke City and County.
Little-known drug manufacturer Regencell Bioscience (NASDAQ: RGC ) saw its shares skyrocket on Tuesday on no apparent catalyst. However, it's possible that the exceptionally distinct business profile — specializing in traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders — caught the attention of speculators.